$Sangamo Therapeutics (SGMO.US)$ 0.9900.981 +28.95% -0.92...

0.9900.981

+28.95%

-0.92%

Sangamo Enters License Agreement With Genentech To Develop Intravenously Administered Genomic Medicines For Neurodegenerative Diseases; Co. Expected To Receive $50M In Near-Term Upfront License Fees And Is Eligible For Up To $1.9B In Milestones

尘埃落定，既成事实，这样的话，投资者们也就放心了。